Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Celebrex · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Celebrex capsule | ACTIVE_COMPARATOR | Commercial capsule |
| D1 | EXPERIMENTAL | Test formulation D1 |
| D2 | EXPERIMENTAL | Test formulation D2 |
| D3 | EXPERIMENTAL | Test formulation D3 |
| Name | Type | Description |
|---|---|---|
| Celebrex | DRUG | - |
| Celebrex capsule | DRUG | Single dose 200 mg commercial Celebrex capsule |
| Test formulation D1 | DRUG | Single dose 150 mg celecoxib as formulation D1 |
| Test formulation D2 | DRUG | Single dose 150 mg celecoxib as formulation D2 |
| Test formulation D3 | DRUG | Single dose 150 mg celecoxib as formulation D3 |
Inclusion Criteria: * diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis; * patients in flare Exclusion Criteria: * any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA * clinical or radiological evidence of chondr...
Celebrex is used for osteoarthritis of the knee and is also studied in healthy volunteers. It is a small molecule developed by Pfizer, Inc. (NYSE: PFE). The drug is currently in Phase 1 clinical development, though completed trials include a Phase 3 study in knee osteoarthritis.
Celebrex is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company is conducting clinical trials of Celebrex in osteoarthritis of the knee and in healthy volunteers.
Celebrex is in Phase 1 clinical development. While a Phase 3 trial in osteoarthritis of the knee has been completed, the current development stage is Phase 1. Celebrex is investigational and still in clinical development.
Celebrex has two completed clinical trials. NCT00137410 was a Phase 3 study of short versus long therapy in osteoarthritis of the knee, enrolling 200 participants in Italy. NCT00925106 was a Phase 1 pharmacokinetics study of celecoxib test formulations in 16 healthy volunteers in the United States.
Celebrex is not FDA approved based on the available data. It is an investigational drug still in clinical development, currently in Phase 1 trials. The completed trials include a Phase 3 study in knee osteoarthritis and a Phase 1 pharmacokinetics study.